News
QIAGEN übertrifft Ausblick für zweites Quartal und erhöht Prognose für das Gesamtjahr 2022
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das zweite Quartal 2022 bekannt und hob die Prognose für das Gesamtjahr 2022 an.
Der Konzernumsatz sank im
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
Net sales for Q2 2022 declined 9% (-4% at
DGAP-Adhoc: MagForce AG: Application for the Opening of Insolvency Proceedings
DGAP-News: Burcon to Present at the Canaccord Genuity 42nd Annual Growth Conference
Simulations Plus Presented New Scientific Developments at PAGE 2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five scientific
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4
Agilent ESG Report Highlights Plans and Progress to Ensure Future Sustainable Growth
Agilent Technologies Inc. (NYSE: A) today released its inaugural Environmental, Social, and Governance (ESG) report, including the company’s first TCFD climate risk report; details on its
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 4, 2022, following the release of its second
DGAP-News: Burcon NutraScience Corp.: Burcon JV, Merit Functional Foods Launches New Peazazz C Pea Protein Ingredient
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to St. Jude Children’s
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
Sartorius Stedim Biotech SA: Information on Document Availability
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Humana Hiring 300 Seasonal Remote Positions
Leading health and well-being company Humana Inc. (NYSE: HUM) announced it is looking to hire about 300 seasonal Enrollment Representatives for nationwide work-from-home positions.
Humana’s
Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided
STAAR Surgical to Report Second Quarter Results on August 10, 2022
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc